Ayurveda already has some well-known strengths—musculo-skeletal disorders, osteoarthritis, lumbar-arthritis, skin disorders like psoriasis among them. What’s needed is ‘translational re-search’ and an emphasis on clinical wisdom, says Dr Sheela Karalam, industrial pharmaceutical researcher, who has to her credit the record of developing and modifying 28 drugs while at Oushadhi, affiliated to the Pharmaceutical Corporation Kerala Ltd. Currently at Vaidyamadom Ayurvedic Research Centre in Thrissur, Kerala, she says this entails taking cues from traditional and clinical practice and developing them in laboratories, guided by scientific principles. This can offer benefits across many traditional practices that exist without any scientific validation, she says. Madhavan, who has specialised in economic and interdisciplinary research in Asian indigenous medicines, too advocates taking a cue from knowledge embedded in tradition and developing it in evidence-based ways. He cites Jeevani, an Ayurvedic product developed out of tribal practice through scientific research, as an example. Rammanohar points to an additional area of urgency within Ayurvedic biomedicine: the need to explore the use of more herbs so as to reduce the stress on the limited numbers of herbs used in formulations. The catalogue of Indian medicinal sources lists about 10,000 herbs, but only 300 are used, and these plants are inevitably over-exploited. Alternative herbs would be a sustainable way to go. But the primary work, he says, is to evolve a conceptual framework—with a rational, universally translatable language—within which to ground the methodology of testing Ayurvedic drug formulations. The present system of testing is based on modern medicine which, says Rammanohar, is inadequate in understanding Ayurvedic formulations.